Greenphire, provider of payment technologies for the clinical trials industry, today announced that Bavarian Nordic, a vaccine-focused biotechnology company based in Denmark, will use Greenphire’s ClinCard Technology Platform in a large, Phase III vaccine trial. The trial will take approximately 1 year and involve 35 investigative sites and more than 4,000 subjects.
Greenphire’s ClinCard system aims to allow Bavarian Nordic to streamline its clinical payment process for the trial, reducing the administrative burden on investigative sites required for reimbursing subjects. The system also aims to enable sites to provide easily accessible, real-time payments to subjects throughout the trial, which has been proven to increase subject retention and compliance.
“Bavarian Nordic is looking forward to collaborating with Greenphire to ensure that payments to the 4,000 subjects involved in this trial will impose a minimal burden on the 35 participating investigative sites and will be easy for subjects to use, helping sites to increase subject retention and compliance,” said Siegfried Rösch, Director of Clinical Operations at Bavarian Nordic.
“We are delighted to be working with Bavarian Nordic and to be implementing our ClinCard technology platform that will ensure all subjects involved in this trial receive payments and reimbursements quickly and with reduced cost, risk, and administrative processes,” said Sam Whitaker, CEO and Co-Founder of Greenphire, “Bavarian Nordic’s decision to use the ClinCard system is an example of how Greenphire’s vision for clinical trial payments is increasingly accepted within the global clinical trials industry.”
The ClinCard System combines global electronic payment technology with real-time messaging functionality to automate clinical trial payments made to trial subjects. Payments are delivered through electronic transfers to a reloadable branded debit card or directly to a subject-specified bank account. The ClinCard System enables subjects to access their funds securely and in real-time. Trial sponsors are able to track and report all payments made from a web-based portal in addition to automating the execution of localized trial-specific messaging to the subject via text, email, or automated voice messages. The ClinCard system reduces costs associated with subject payments by up to 60%, reduces administrative steps by 90%, and has demonstrated increased subject retention by as much as 12%.
For further information on Greenphire and its innovative solutions please email: [email protected], call +1 215-609-4640 or visit www.greenphire.com.
Related Links:
Technology Helps Trim Reimbursement Times
Greenphire, Merge Healthcare Integrate Clinical Payment/EDC Platforms
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.